| Nominations Are Now Being Accepted for the Panel on Opportunistic Infections in Adults and Adolescents with HIV The Panel on Opportunistic Infections in Adults and Adolescents with HIV is accepting nominations for new scientific/clinical members with expertise in HIV medicine and opportunistic infections. The Panel is seeking candidates for appointment to Panel subgroups, which focus on one pathogen or one group of pathogens, with qualifications as follows: - Clinical investigators with expertise in the treatment and prevention of HIV-related opportunistic infections
- Active clinicians with extensive experience managing persons with HIV and their opportunistic infections
- Clinical Pharmacists with expertise in infectious diseases
Panel members are expected to have strong writing skills, to stay up to date on literature appropriate to their Panel subgroup, and to be available to participate in most conference calls that may be as frequent as once a month. The Panel has strict financial disclosure and conflict of interest rules with which prospective members must comply.
Panel members critically evaluate new information and prepare guideline revisions. The successful candidates will serve a 3-year term with appointments, with potential for reappointment for additional terms.
The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of more than 100 members who are clinicians, researchers, academicians, and Department of Health and Human Services (HHS) representatives with expertise in HIV and opportunistic infection management in the United States.
The Panel subgroups meet every 1 to 3 months via teleconference to review and critically evaluate emerging scientific data relating to their pathogen(s) subgroup, and to propose revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, which is found at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines.
Panel members are not financially compensated for their time commitment and effort.
Panel members must not have exclusionary conflicts of interest,which will be assessed and adjudicated by Panel leadership.
The nomination should include a curriculum vitae and a letter of interest or a letter of nomination (from a colleague) with specific reference to how the nominee would contribute to the work of the Panel, especially in the areas noted above. Self-nomination is welcome.
All supporting documents should be submitted to Lauren Davis at lauren.davis2@nih.gov by January 15, 2021.
Panel Subgroups:
- Bartonellosis
- Candidiasis
- Chagas Disease
- Coccidioidomycosis
- Community-Acquired Pneumonia
- Cryptococcosis
- Cryptosporidiosis
- Cystoisosporiasis (Isosporiasis)
- Cytomegalovirus Bacterial Enteric Infections
- Hepatitis B Virus
- Hepatitis C Virus
- Herpes Simplex Virus
- Histoplasmosis
- Human Herpesvirus-8
- Human Papillomavirus
- Leishmaniasis
- Malaria
- Microsporidiosis
- Mycobacterium tuberculosis
- Pneumocystis Pneumonia
- PML/JCV
- Syphillis
- Talaromycosis (Penicilliosis)
- Toxoplasma gondii
- Varicella-Zoster Virus
Offering the federally approved HIV/AIDS clinical treatment and prevention guidelines, as well as other HIV research information for health care providers, researchers, people affected by HIV/AIDS, and the general public.
*HIVinfo continues to finalize the transition from AIDSinfo to HIVinfo. E-newsletters will be coming from an HIVinfo email address soon. Thank you for your patience.* |
No comments:
Post a Comment